Compare DexCom, Inc. (DXCM) vs Newmont Corporation (NEM) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Newmont Corporation (NEM) trades at $94.75, up 1.77% on the day, while technical indicators show a bearish trend despite recent earnings beats. The company demonstrates strong fundamentals with Q1 2026 revenue up 46% to $7.31 billion and record $3.1 billion free cash flow, supported by a 33.87% net income margin. Analyst consensus remains strongly bullish with 27 buy ratings and a $140.11 price target, representing 48% upside potential from current levels.

The investment outlook is positive given attractive valuation multiples (P/E 12.35, EV/EBITDA 6.07), robust cash generation, and shareholder returns including dividends and buybacks. Key risks include gold price volatility, rising unit costs in 2026, and broader market sentiment toward mining stocks. The company's strong balance sheet with $3.64 billion cash and net cash position provides resilience during commodity cycles.